KRT7 Antibody for IHC / Keratin 7, 100ug

Cytokeratin 7 (KRT7), commonly referred to as CK7, is a type II intermediate filament protein expressed in simple, glandular, and transitional epithelia, where it contributes to cytoskeletal stability and epithelial organization. It is widely distributed in epithelial tissues including lung, breast, ovary, endometrium, and urinary tract, and is largely absent from most stratified squamous epithelia. Because of this characteristic expression pattern, Cytokeratin 7 is one of the most widely used epithelial markers in immunohistochemistry for evaluating tissue origin and differentiation. Cytokeratin 7 Antibody for IHC enables clear cytoplasmic detection of KRT7 in formalin-fixed, paraffin-embedded tissues, where staining highlights glandular and ductal epithelial cell populations with high specificity.<br><br>Cytokeratin 7 antibody, also referred to as KRT7 antibody or CK7 antibody in the literature, recognizes a cytoplasmic intermediate filament protein localized within epithelial cells. This Cytokeratin 7 Antibody for IHC is optimized for Tissue Microarray (TMA)-based immunohistochemistry, enabling standardized, side-by-side evaluation of epithelial marker expression across large panels of normal and cancer tissues. In normal tissue TMAs, strong cytoplasmic HRP-DAB brown staining is consistently observed in glandular epithelia including bronchial epithelium, breast ducts, endometrial glands, and urothelium, while squamous epithelia and mesenchymal tissues remain largely negative, producing a clear and interpretable staining contrast across tissue types.<br><br>In cancer tissue microarrays, Cytokeratin 7 expression is frequently observed in adenocarcinomas and tumors derived from glandular or transitional epithelia, including lung, breast, ovarian, and endometrial carcinomas. Cytoplasmic staining highlights tumor epithelial cells and supports classification of tumor origin, particularly in distinguishing CK7-positive adenocarcinomas from CK7-negative malignancies. This pattern is especially valuable in the context of CK7/CK20 immunohistochemical profiling, where Cytokeratin 7 expression provides key diagnostic context for differentiating primary tumor sites and epithelial lineage in metastatic disease models.<br><br>Tissue Microarray (TMA) analysis enables direct comparison of KRT7 expression across dozens of tissue types under identical staining conditions, demonstrating highly reproducible and consistent cytoplasmic staining in glandular epithelia and epithelial-derived tumors, alongside minimal background in non-expressing tissues. Clone MSVA-607R produces strong, well-defined staining across TMA panels, allowing clear identification of epithelial compartments and facilitating comparative pathology studies. The observed staining distribution aligns with known KRT7 biology and publicly available datasets such as the Human Protein Atlas, supporting the reliability of this antibody in large-scale immunohistochemistry analysis.<br><br>The differential expression of Cytokeratin 7 between glandular and squamous epithelia adds important interpretive value in IHC-based studies, where absence of CK7 staining can support identification of squamous differentiation, while positive staining reinforces glandular or transitional epithelial origin. This contrast enhances the utility of Cytokeratin 7 in studies of epithelial classification, tumor differentiation, and tissue-specific expression patterns.<br><br>This antibody targets Cytokeratin 7 in research applications requiring robust and interpretable immunohistochemical detection of epithelial and glandular differentiation markers, making it well suited for Tissue Microarray-based studies, epithelial biology research, and tumor classification.<br><br>This antibody is part of the <a href=../cytokeratin-7-antibody-ck7.html>Cytokeratin 7 antibody collection</a>, where additional KRT7/CK7 antibodies for various applications can be explored.<br><br>This antibody is also part of a broader collection of <a href='/ihc-antibodies-tissue-microarray-validated.html'>IHC antibodies validated by tissue microarray analysis</a>, supporting consistent staining across normal and cancer tissues.

Specifications